XP-002097957

- 1/1 (C) WPI / DERWENT
- AN 89-019644 ç25!
- AP JP870129551 870526
- PR JP870129551 870526
- TI Enteric anticoagulation thrombolytic drug contains protease with plasminogen activator activity, having low toxicity etc.
- IW ENTERAL ANTICOAGULANT THROMBOLYTIC DRUG CONTAIN PROTEASE PLASMINOGEN ACTIVATE ACTIVE LOW TOXIC
- PA (KAOS) KAO CORP
- PN JP63295515 A 881201 DW8903 004pp
- ORD 1988-12-01
- IC A61K37/54
- FS CPI
- DC B04 D16
- AB J63295515 An anticoagulation thrombolytic drug contains as active ingredient a protease having plasminogen activator activity.
 - The protease having plasminogen activator activity is e.g. prourokinase, tissue plasminogen activator, trypsin, kallikrein, thrombin, bromelain, etc.. Entric coating is e.g. of ethyl acrylate/methacrylic acid copolymer, hydroxypropyl methyllose cellulose acetate succinate, etc. The dose may bel50,00 to 200,000 urokinase units per day for adult.
 - USE/ADVANTAGE The protease can be easily administered orally with good effect, and has low toxicity and side effects.